Last price
US$ 27,72
0,00% on 14/09/2026
Fundamentals
20,38
Relação entre o preço da ação e o lucro por ação (LPA) informado pela fonte de dados.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
1,83
Compara o preço de mercado de uma ação ou cota com o valor contábil/patrimonial por ação ou cota (VPA).
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
6,21%
Percentual pago em proventos nos 365 dias anteriores ao cálculo em relação ao preço usado na coleta.
Income history
| Type | Ex-date | Payment date | Value/share |
|---|---|---|---|
| dividendo | — | 01/09/2026 | US$ 0,43 |
| dividendo | — | 12/06/2026 | US$ 0,43 |
| dividendo | — | 06/03/2026 | US$ 0,43 |
| dividendo | — | 01/12/2025 | US$ 0,43 |
| dividendo | — | 02/09/2025 | US$ 0,43 |
| dividendo | — | 13/06/2025 | US$ 0,43 |
| dividendo | — | 07/03/2025 | US$ 0,43 |
| dividendo | — | 02/12/2024 | US$ 0,42 |
| dividendo | — | 03/09/2024 | US$ 0,42 |
Context
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
8,99%
Relação entre o lucro atribuível aos controladores e o patrimônio líquido atribuível aos controladores.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
12,42%
De cada R$ 1,00 de receita, quanto sobra como lucro depois de todos os custos, despesas e impostos.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
—
Quanto de lucro operacional (após impostos) a empresa gera para cada real de capital investido no negócio — próprio e de terceiros.
—
Quantos anos de geração de caixa operacional (EBITDA) a dívida líquida de uma empresa representa — uma medida de alavancagem.
US$ 1,36
Valor de lucro por ação informado pela fonte de dados da empresa.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
US$ 15,17
Quanto do patrimônio contábil da empresa (ou do fundo) corresponde a cada ação ou cota.
Where it came from, when we collected it and what the number doesn't say. It's the data's origin, never a judgment on the asset.
Reference: 31/12/2025 · All indicators: Financial Modeling Prep (FMP)
Net revenue (fiscal year)
US$ 62,6 bi
Cash (quarter)
US$ 1,1 bi
Market cap
US$ 158,0 bi
Operating cash flow (fiscal year)
—
| dividendo | — | 14/06/2024 | US$ 0,42 |